Harnessing Neurotrophin-3 Biology to Address the Drivers of Chronic Pain

2:00 pm - Wednesday 27th January 2027

  • Exploring the role of neurotrophins, particularly NT-3, in regulating pain signalling, inflammation, and chronic pain sensitisation
  • Examining the biological rationale for selectively targeting NT-3 to address pain and functional impairment in osteoarthritis
  • Reviewing how LEVI-04, an investigational p75NTR-Fc fusion protein, modulates NT-3 signalling and its clinical effects in patients with osteoarthritis
  • Highlighting findings from a novel pain-evoked endpoint alongside future development plans in osteoarthritis and neuropathic pain indications

Speakers:

Founder & Chief Scientific Officer
Levicept